LAPS score for individualized treatment of advanced EGFR-mutated non-small cell lung cancer receiving EGFR-TKIs with or without bevacizumab

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):1–10. doi: 10.3322/caac.21660.
   Web of Science ®Google Scholar
• Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun. 2021;41(10):1037–1048. doi: 10.1002/cac2.12197.
   PubMed Web of Science ®Google Scholar
• Melosky B, Kambartel K, Hantschel M, et al. Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis. Mol Diagn Ther. 2022;26(1):7–18. doi: 10.1007/s40291-021-00563-1.
   PubMed Web of Science ®Google Scholar
• Ma F, Laster K, Dong Z. The comparison of cancer gene mutation frequencies in Chinese and U.S. patient populations. Nat Commun. 2022;13(1):5651. doi: 10.1038/s41467-022-33351-4.
   PubMed Web of Science ®Google Scholar
• Gray JE, Okamoto I, Sriuranpong V, et al. Tissue and plasma EGFR mutation analysis in the FLAURA trial: osimertinib versus comparator EGFR tyrosine kinase inhibitor as First-line treatment in patients with EGFR-mutated advanced Non-Small cell lung cancer. Clin Cancer Res. 2019;25(22):6644–6652. doi: 10.1158/1078-0432.CCR-19-1126.
   PubMed Web of Science ®Google Scholar
• Westover D, Zugazagoitia J, Cho BC, et al. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29(suppl_1):i10–i19. doi: 10.1093/annonc/mdx703.
   PubMed Web of Science ®Google Scholar
• Le X, Nilsson M, Goldman J, et al. Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC. J Thorac Oncol. 2021;16(2):205–215. doi: 10.1016/j.jtho.2020.10.006.
   PubMed Web of Science ®Google Scholar
• Frezzetti D, Gallo M, Maiello MR, et al. VEGF as a potential target in lung cancer. Expert Opin Ther Targets. 2017;21(10):959–966. doi: 10.1080/14728222.2017.1371137.
   PubMed Web of Science ®Google Scholar
• Schicher N, Paulitschke V, Swoboda A, et al. Erlotinib and bevacizumab have synergistic activity against melanoma. Clin Cancer Res. 2009;15(10):3495–3502. doi: 10.1158/1078-0432.CCR-08-2407.
   PubMed Web of Science ®Google Scholar
• Kawashima Y, Fukuhara T, Saito H, et al. Bevacizumab plus erlotinib versus erlotinib alone in japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Respir Med. 2022;10(1):72–82. doi: 10.1016/S2213-2600(21)00166-1.
   PubMed Web of Science ®Google Scholar
• Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20(5):625–635. doi: 10.1016/S1470-2045(19)30035-X.
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Seto T, Nishio M, et al. Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: survival follow-up results of the randomized JO25567 study. Lung Cancer. 2021;151:20–24. doi: 10.1016/j.lungcan.2020.11.020.
   PubMed Web of Science ®Google Scholar
• Zhao B, Zhang W, Yu D, et al. Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials. Lung Cancer. 2018;122:10–21. doi: 10.1016/j.lungcan.2018.05.011.
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi: 10.1158/1078-0432.CCR-04-0713.
   PubMed Web of Science ®Google Scholar
• Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition lung cancer stage classification. Chest. 2017;151(1):193–203. doi: 10.1016/j.chest.2016.10.010.
   PubMed Web of Science ®Google Scholar
• Gao S, Wu M, Chen Y, et al. Actic dehydrogenase to albumin ratio in prediction of unresectable pancreatic cancer with intervention chemotherapy. Future Oncol. 2018;14(14):1377–1386. doi: 10.2217/fon-2017-0556.
   PubMed Web of Science ®Google Scholar
• Peng R-R, Liang Z-G, Chen K-H, et al. Nomogram based on lactate dehydrogenase-to-albumin ratio (LAR) and platelet-to-lymphocyte ratio (PLR) for predicting survival in nasopharyngeal carcinoma. J Inflamm Res. 2021;14:4019–4033. volumedoi: 10.2147/JIR.S322475.
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhou Y, Cao Y, et al. Nomograms based on lactate dehydrogenase to albumin ratio for predicting survival in colorectal cancer. Int J Med Sci. 2022;19(6):1003–1012. doi: 10.7150/ijms.71971.
   PubMed Web of Science ®Google Scholar
• Aday U, Tatli F, Akpulat FV, et al. Prognostic significance of pretreatment serum lactate dehydrogenase-to-albumin ratio in gastric cancer. Contemp Oncol. 2020;24(3):145–149. doi: 10.5114/wo.2020.100219.
   Google Scholar
• Xie Z, Zhou H, Wang L, et al. The significance of the preoperative lactate dehydrogenase/albumin ratio in the prognosis of colon cancer: a retrospective study. Peer J. 2022;10:e13091. doi: 10.7717/peerj.13091.
   PubMed Web of Science ®Google Scholar
• Rotondo FS, Gabril A, Filter M, et al. Lactate dehydrogenase a is a potential prognostic marker in clear cell renal cell carcinoma. Mol Cancer. 2014;13:101. doi: 10.1186/1476-4598-13-101.
   PubMed Web of Science ®Google Scholar
• Hermes A, Gatzemeier U, Waschki B, et al. Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer – a retrospective single institution analysis. Respir Med. 2010;104(12):1937–1942. doi: 10.1016/j.rmed.2010.07.013.
   PubMed Web of Science ®Google Scholar
• Danner BC, Didilis VN, Wiemeyer S, et al. Long-term survival is linked to serum LDH and partly to tumour LDH-5 in NSCLC. Anticancer Res. 2010;30(4):1347–1351.
   PubMed Web of Science ®Google Scholar
• Fiala O, Pesek M, Finek J, et al. Change in serum lactate dehydrogenase is associated with outcome of patients with advanced-stage NSCLC treated with erlotinib. Anticancer Res. 2016;36(5):2459–2465.
   PubMed Web of Science ®Google Scholar
• Ng IK, Kumarakulasinghe NB, Syn NL, et al. Development, internal validation and calibration of a risk score to predict survival in patients with EGFR-mutant non-small cell lung cancer. J Clin Pathol. 2021;74(2):116–122. doi: 10.1136/jclinpath-2020-206754.
   PubMed Web of Science ®Google Scholar
• Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9(1):69. doi: 10.1186/1475-2891-9-69.
   PubMed Web of Science ®Google Scholar
• Li Q, Kong F, Ma J, et al. Nomograms based on fibrinogen, albumin, neutrophil-Lymphocyte ratio, and carbohydrate antigen 125 for predicting endometrial cancer prognosis. Cancers (Basel). 2022;14(22):5632. doi: 10.3390/cancers14225632.
   PubMed Web of Science ®Google Scholar
• Lis CG, Gupta D, Lammersfeld CA, et al. Role of nutritional status in predicting quality of life outcomes in cancer–a systematic review of the epidemiological literature. Nutr J. 2012;11(1):27. 24 doi: 10.1186/1475-2891-11-27.
   PubMedGoogle Scholar
• Mori S, Usami N, Fukumoto K, et al. The significance of the prognostic nutritional index in patients with completely resected non-small cell lung cancer. PLoS One. 2015;10(9):e0136897. doi: 10.1371/journal.pone.0136897.
   PubMed Web of Science ®Google Scholar
• Payen T, Trédaniel J, Moreau L, et al. Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: results from the EGFR-2013-CPHG study. Respir Med Res. 2021;80:100795. doi: 10.1016/j.resmer.2020.100795.
   PubMedGoogle Scholar
• Cha YK, Lee HY, Ahn MJ, et al. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin Lung Cancer. 2015;16(3):228–236. doi: 10.1016/j.cllc.2014.11.002.
   PubMed Web of Science ®Google Scholar